Interim Report Q1 2020

On May 26, 2020 Oncopeptides reported that Interim Report Q1 2020 (Press release, Oncopeptides, MAY 26, 2020, View Source [SID1234558444])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Financial overview January 1 – March 31, 2020
Net sales amounted to SEK 0.0 M (0.0)
Loss for the period was SEK 297.3 M (loss: 134.1)
Loss per share, before and after dilution, was SEK 5.37 (loss: 2.82)
On March 31 cash and cash equivalents amounted to SEK 617.8 M (747.5)
Significant events during the period January 1 – March 31, 2020
Top line results from the company’s pivotal phase 2 study HORIZON were presented and showed a 26% Overall Response Rate (ORR) of melflufen in triple-class refractory multiple myeloma patients
The Lancet Haematology published detailed results from Oncopeptides international multi¬center study, O-12-M1
Oncopeptides announced that COVID-19 will not affect the company’s pivotal studies sig¬nificantly while recruitment to explorative studies and initiating new studies will temporar¬ily be paused
The company strengthened its management team with several new senior executives
Significant events after the reporting period
In May, Oncopeptides completed a directed share issue of SEK 1,414 million (144 MUSD) before issue costs
The enrollment in the pivotal phase 3 study OCEAN was successfully completed in May including 450 patients from more than 100 hospitals around the world
Financial overview of the group
2020
Jan – Mar 20191)
Jan – Mar 2019
Jan – Dec
Net sales – – –
Operating loss -296,876 -133,812 -739,392
Loss before tax -297,327 -133,946 -739,920
Loss for the period -297,329 -134,077 -740,705
Earnings per share before and after
dilution (SEK) -5.37 -2.82 -14.33
Cash flow from operating activities -312,841 -142,821 -690,566
Cash and cash equivalents at the end of the period 617,786 747,471 926,186
Research & development costs/operating expenses % 72% 80% 74%
1) Earlier periods have been adjusted to reflect correction of errors, see note 6.

Conference call for investors, analysts and the media
The Interim Report Q1 2020 and an operational update will be presented by CEO Jakob Lindberg and members of Oncopeptides management team, Tuesday May 26, 2020 at 10:00 (CET). The conference call will also be streamed via a link on the website: www.oncopeptides.com.

Boston Scientific to Participate in Jefferies 2020 Healthcare Conference

On May 26, 2020 Boston Scientific Corporation (NYSE: BSX) reported to participate in the Jefferies 2020 Virtual Healthcare Conference on June 2 (Press release, Boston Scientific, MAY 26, 2020, View Source [SID1234558461]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Joe Fitzgerald, executive vice president and president, Rhythm Management; Kenneth Stein, M.D., senior vice president and chief medical officer, Global Health Policy and Rhythm Management; Mark Bickel, vice president, controller, Rhythm Management; and Susie Lisa, vice president, Investor Relations will participate in a 25-minute question-and-answer session with the host analyst beginning at approximately 8 a.m. EDT.

A live webcast and replay of the webcast will be accessible at investors.bostonscientific.comView Source The replay will be available beginning approximately one hour following the completion of the event.

Immunocore announces dosing of first patient with fourth ImmTAC®

On May 26, 2020 Immunocore (or the "Company"), a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialise a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease, reported the start of the first-in-human clinical trial of IMC-F106C, the fourth bispecific developed using the Company’s innovative ImmTAC technology platform (Press release, Immunocore, MAY 26, 2020, View Source [SID1234558477]). Wholly owned IMC-F106C is focused on targeting tumours that express PRAME, a cancer-testis antigen (CTA) that is highly expressed in a broad range of solid and hematologic malignancies, and is being developed by Immunocore.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The trial (IMC-F106C-101) is designed to study the safety and preliminary activity of IMC-F106C as a monotherapy and in combination with a checkpoint inhibitor in patients with PRAME-expressing cancers.

"IMC-F106C is designed to re-direct T cells to attack PRAME expressing tumours. PRAME is an important target since it is broadly expressed in metastatic non-small cell lung cancer and other tumours of unmet need," said David Berman, Head of Research and Development at Immunocore. "The start of this study is another significant milestone for Immunocore and we are pleased that clinical development has continued despite these unprecedented times as we aim to deliver medicines to transform patients’ lives."

Alpine Immune Sciences to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference

On May 26, 2020 Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, reported its participation in an analyst-led fireside chat at the Jefferies Virtual Global Healthcare Conference on Tuesday, June 2, at 10:00 a.m. ET (Press release, Alpine Immune Sciences, MAY 26, 2020, View Source [SID1234558495]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available online in the investor relations section of the company’s website at View Source A replay of the presentation will be available on the company website for 90 days following the webcast.

Selvita Reports Financial Results for Q1 2020: Dynamic Increase in Backlog for 2020 and Strong Position on the Market

On May 26, 2020 Selvita (WSE: SLV), one of the largest preclinical contract research organizations in Europe, reported its first quarter 2020 financial results and provided a corporate update (Press release, Selvita, MAY 26, 2020, View Source [SID1234558512]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company continues its dynamic growth and reports backlog for 2020 of EUR 21,8 million, indicating a 41% increase to the values reported a year ago. The increase in the value of signed contracts in the Services segment amounted to 48%.

For the first three months of 2020, Selvita reports consolidated revenues of EUR 7 million, up by 41% on a year-on-year basis, thus confirming very good preliminary estimates published on April 29, 2020. What is quite remarkable, despite the worldwide COVID-19 pandemic, the company has managed to strengthen its position in the global CRO market, especially among US customers considered the largest biotechnology market in the world.

Commercial revenues in the Services Segment amounted to EUR 5.8 million in 1Q 2020, indicating a 46% increase as compared to same period previous year. The Bioinformatics Segment’s (Ardigen, where Selvita holds 54,7 percent of votes at the General Meeting of Shareholders) commercial revenues increased by 33% and amounted to EUR 0.7 million.

Company’s EBITDA profit reached EUR 1.7 million and was by 52% higher than in Q1 2019, with a profitability margin of nearly 24%. The net result increased by 92% reaching EUR 0.8 million. These results, demonstrate that Selvita has not only maintained but in fact exceed its planned rate of growth.

– We’re sticking to the plan and not slowing down our pace of development. We’re maintaining high revenue dynamics, at the same time increasing EBITDA margin, which in Q1 2020 has increased by nearly 2 p.p. The results we managed to achieve in the past quarter are particularly satisfying, due to the global economic uncertainty caused by COVID-19 pandemic. So far, it looks like Selvita successfully went through this difficult time. We implemented safety measures in order to secure the health and safety of our employees and managed to maintain business continuity in all projects. In this uncertain environment, we were able to strengthen our position among foreign customers, especially on the U.S. market. Many pharmaceutical and biotechnology companies have realized the need for geographical diversification of outsourced services. Selvita skillfully fits into these changing trends on the preclinical CRO market – comments Bogusław Sieczkowski, co-founder, and Chief Executive Officer at Selvita.

External revenues from the services commissioned by US customers increased in Q1 2020 by 175% and already constitute over 25% of the entire Services Segment revenues. At the same time, revenues from the services commissioned by customers from the United Kingdom increased by 74%. Services contracts from these two largest global biotech & pharma markets include both drug discovery and regulatory research. Increasing customer recognition for the high quality of services and competences offered by Selvita team results in further contracts. As on May 21, the backlog in the Service Segment amounted to EUR 18.0 million, i.e. was 48% higher than same time previous year. Out of which, nearly EUR 14.0 million concerns the services in the area of drug discovery and EUR 3.5 million in regulatory research.

– The continuously growing backlog, demonstrates that during the pandemic, despite the restrictions placed on international travel and cancelation of industry events, we are able to acquire new contracts efficiently. With most of global business activity going virtual, the geographical barriers have disappeared and we can build our position on the international market on an equal level with other providers – emphasizes Bogusław Sieczkowski.

In addition to increasing revenues, Selvita’s new strategy also assumes maintaining a stable EBITDA margin and over EUR 230 million of market cap in 2023. For this purpose, in 2020-2023, the company intends to execute investments worth up to EUR 75-90 million, which will be allocated to acquisitions and organic development.

In order to execute the strategy, Selvita plans to raise approx. EUR 21 million by issuing up to 15% of the share capital in a Follow-On offering. Approximately 80% of the proceeds will be allocated for acquisitions. One of the elements of the strategy execution will be the creation of Selvita Research Center in order to secure own research space necessary for further growth. The Company has already made a first step towards execution of this aim, and signed a preliminary contract for a plot of land in the neighborhood of its current laboratories. The initiation of the investment is planned for 2021.